Semaglutide, the way a clinician reads it

What semaglutide is

Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. Structurally, it is an acylated peptide that shares roughly 94% homology with native human GLP-1^[17]. Two engineering choices give it a roughly one-week duration of action: an alpha-aminoisobutyric acid (Aib) substitution at position 8 that blocks dipeptidyl peptidase-4 (DPP-4) cleavage, and a C-18 fatty di-acid side chain at lysine-26 that drives >99% albumin binding^[17].

The molecule is small by biologic standards — 4,113.64 Da — but it behaves pharmacokinetically more like a slow-release depot than a conventional peptide. Subcutaneous bioavailability is 89%, time to peak is 1–3 days, and elimination occurs through proteolytic backbone cleavage and beta-oxidation of the fatty acid tail rather than through cytochrome P450 metabolism^[17]. The result is a once-weekly dosing schedule that has reshaped GLP-1 therapy.

There is also an oral formulation. Co-formulating semaglutide with the absorption enhancer SNAC raises oral bioavailability into the 0.4–1% range, which is enough — given the molecule’s potency and half-life — to support once-daily dosing of 3 mg, 7 mg, or 14 mg tablets for type 2 diabetes^[5]. High-dose oral semaglutide (25 mg and 50 mg) was investigated in the PIONEER PLUS Phase 3b trial and outperformed the 14 mg dose for both HbA1c and weight reduction^[20].

How it works

Selective GLP-1 receptor agonism produces a coordinated set of metabolic effects^[17]:

• On pancreatic beta cells, semaglutide augments glucose-dependent insulin secretion, which lowers HbA1c without causing baseline hypoglycemia.
• On alpha cells, it suppresses inappropriate glucagon release.
• Through vagal signaling, it slows gastric emptying — the mechanism behind both the satiety effect and the dominant gastrointestinal side effects.
• In the hypothalamus, it activates POMC/CART neurons and inhibits AgRP/NPY signaling to reduce appetite.
• In the hindbrain (area postrema and nucleus tractus solitarius), it activates circuits that contribute to satiety — and to nausea.

These mechanisms explain why a single molecule has produced trial wins across glycemic control, weight loss, atherosclerotic event reduction, kidney outcomes, and steatohepatitis: the underlying biology of GLP-1 signaling intersects pancreatic, central nervous, cardiovascular, renal, and hepatic disease.

What semaglutide is approved for

The FDA has approved semaglutide for five distinct clinical indications, each built on a different Phase 3 program:

1. Type 2 diabetes mellitus — glycemic control. First approved December 2017 (subcutaneous, based on the SUSTAIN program) and September 2019 (oral, based on PIONEER).
2. Chronic weight management in adults with BMI >=30, or BMI >=27 with a weight-related comorbidity. Approved June 2021 based on the STEP program.
3. Chronic weight management in adolescents aged 12 and older with obesity. Approved December 2022 based on STEP TEENS.
4. Cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity, without diabetes. Approved March 2024 based on the SELECT trial.
5. Reduced risk of kidney function worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Approved 2025 based on the FLOW trial.

A submission for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis was accepted with Priority Review following the positive ESSENCE Phase 3 results published in June 2025^[11].

This is an unusually broad indication list for a single molecule. It reflects the way GLP-1 receptor signaling sits at the crossroads of the cardiometabolic, renal, and hepatic axes — and the way Novo Nordisk’s clinical-development program has methodically tested each.

What the trial data actually shows

Each Phase 3 program has produced a headline number worth knowing:

• SUSTAIN-6 (n=3,297, T2DM at high CV risk): MACE composite 6.6% vs 8.9% placebo over 104 weeks, HR 0.74 (95% CI 0.58–0.95)^[1].
• STEP 1 (n=1,961, obesity without diabetes): mean body weight change −14.9% vs −2.4% placebo over 68 weeks; 86% achieved >=5% loss; 50% achieved >=15%^[2].
• SELECT (n=17,604, established CVD with overweight/obesity, no diabetes): MACE composite 6.5% vs 8.0%, HR 0.80 (95% CI 0.72–0.90), mean ~40 months^[3].
• FLOW (n=3,533, T2DM with CKD): composite kidney/CV-death outcome HR 0.76 (95% CI 0.66–0.88); trial stopped early for efficacy^[4].
• ESSENCE Part 1 (n=800, MASH with fibrosis stage 2 or 3): MASH resolution without fibrosis worsening at 72 weeks 62.9% vs 34.3% placebo; fibrosis improvement 36.8% vs 22.4%^[11].

Long-term durability has been documented as well. The SELECT four-year weight-loss analysis showed a sustained −10.2% body weight reduction at 208 weeks, a −8.7 percentage-point treatment difference vs placebo^[15]. By contrast, the STEP 1 trial extension showed that about two-thirds of weight loss is regained within a year of stopping semaglutide — the empirical case for chronic-disease framing of obesity pharmacotherapy^[14].

The research page walks through each pivotal trial in detail. The dosage page covers FDA-approved dosing schedules. The FAQ page answers the questions clinicians and prospective patients ask most often — including which specialties have driven the trial program and what credentials matter when a clinician is the one writing the prescription.